Corporate News

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that following the Company's recent admission to trading on AIM ("Admission") and upon the recommendation of the Company's remuneration committee, it has formally allocated to certain of its directors, persons discharging managerial responsibilities ("PDMRs") and employees the options over a total of 9,619,200 ordinary shares of 0.00037p each in the Company ("Ordinary Shares") that were granted at Admission pursuant to Polarean's Pre-Admission Share Option Scheme dated 12 December 2017 (the "Options").

The exercise price for the Options is 15 pence being the price at which Polarean's Ordinary Shares were placed at Admission. The Options will vest in equal portions on an annual basis on the anniversary of Admission, over a four year period from the date of Admission. The options term expires on 29 March 2028.

Options Granted to Directors and PDMRs

As per the table below, a total of 8,122,822 have been granted to Directors and PDMRs of Polarean:

Following the formal grant of Options referred to above, there are 24,469,061 outstanding options and warrants over Polarean's Ordinary Shares, representing 25% of the Company's Ordinary Shares and total voting rights on a fully diluted basis.

Issue of Equity

In addition, Polarean has issued a total of 2,772 new Ordinary Shares to holders of convertible loan notes ("CLNs") that were issued in December 2017, when the Group undertook a pre-Admission fundraise, in lieu of interest payable on the CLNs (the "CLN Interest Shares").

Application will be made for CLN Interest Shares, which will rank pari passu with the existing Ordinary Shares, to be admitted to trading on AIM and this is expected to occur at 8.00 a.m. on 24 April 2018.

Following the admission of the CLN Interest Shares, the total number of voting rights in the Company will be 73,409,464 Ordinary Shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.